BenzingaOctober 20, 2026 at 4:36 AM NY7 Days Ago
Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027
ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
